Ligand validation:5AFM

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5AFM designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5AFM_NAG_C_301	68%	24%	0.105	0.927	1.4	1.68	3	5	1	0	93%	0.9333
5AFM_NAG_D_301	58%	18%	0.139	0.931	1.31	2.23	2	5	5	0	93%	0.9333
5AFM_NAG_E_301	57%	28%	0.147	0.936	1.25	1.63	3	4	6	0	93%	0.9333
5AFM_NAG_E_302	33%	18%	0.171	0.863	1.59	1.95	4	4	3	0	93%	0.9333
5AFM_NAG_B_301	29%	27%	0.183	0.853	1.3	1.61	3	5	3	0	93%	0.9333
5AFM_NAG_A_301	23%	24%	0.199	0.836	1.35	1.73	3	5	4	0	93%	0.9333
5AFM_NAG_A_302	20%	19%	0.22	0.831	1.55	1.91	4	4	2	0	93%	0.9333
5AFM_NAG_D_302	7%	19%	0.287	0.761	1.54	1.91	3	4	3	0	93%	0.9333
5AFM_NAG_B_302	4%	15%	0.302	0.696	1.71	2.07	6	4	2	0	93%	0.9333
5AFM_NAG_C_302	2%	17%	0.332	0.642	1.59	1.97	4	4	1	0	93%	0.9333
5AFN_NAG_A_301	62%	38%	0.09	0.891	0.62	1.76	-	4	1	0	93%	0.9333
4HQP_NAG_B_803	28%	66%	0.241	0.893	0.69	0.63	-	-	1	0	100%	0.9333
3SQ9_NAG_C_901	15%	61%	0.11	0.671	0.98	0.54	1	-	3	0	100%	0.9333
3SQ6_NAG_H_901	14%	53%	0.142	0.685	0.95	0.86	1	1	2	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3PPS_NAG_B_760	100%	44%	0.028	0.993	0.57	1.57	-	3	0	0	100%	0.9333
5O59_NAG_A_601	100%	70%	0.024	0.993	0.3	0.85	-	-	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.